Safety of Quadrivalent Human Papillomavirus Vaccine Administered Routinely to Females

Abstract

The quadrivalent human papillomavirus vaccine was associated with same-day syncope and skin infections in the 2 weeks after vaccination. This study did not detect evidence of new safety concerns among females 9 to 26 years of age secondary to vaccination with HPV4.